Wyeth Extends Agreement with Affymetrix to 15 Years
October 24 2006 - 7:00AM
Business Wire
Affymetrix Inc. (Nasdaq: AFFX) announced today that Wyeth (NYSE:
WYE) has signed another agreement with Affymetrix to use GeneChip�
microarray technology for three more years, further extending the
relationship that began in 1994. Under the agreement, Wyeth will
continue to apply Affymetrix technology in numerous areas of the
drug discovery and development process. Wyeth was one of the first
pharmaceutical companies to apply genomics in clinical research.
The company will continue to use Affymetrix microarray technology
to identify new drug targets and gain a better understanding of the
genetic markers that potentially correlate with a patient�s
response to therapy. The latest GeneChip technology enables them to
more accurately classify disease, predict clinical progression and
determine likelihoods of treatment success in ways never before
possible. �Wyeth has been a pioneer in demonstrating the power of
Affymetrix microarray technology in the entire drug discovery and
development process,� said Chip Leveille, vice president,
Pharmaceutical Business Unit at Affymetrix. �We anticipate that a
better understanding of human genetic variations and the ability to
look at the entire genome in greater detail will dramatically
accelerate research and, ultimately, help bring more effective
tests and therapies to market faster.� About Affymetrix Affymetrix
scientists invented the world's first high-density microarray in
1989 and began selling the first commercial microarray in 1994.
Since then, Affymetrix GeneChip� technology has become the industry
standard in molecular biology research. Affymetrix technology is
used by the world's top pharmaceutical, diagnostic and
biotechnology companies as well as leading academic, government and
not-for-profit research institutes. More than 1,400 systems have
been installed around the world and more than 7,000 peer-reviewed
papers have been published using the technology. Affymetrix'
patented photolithographic manufacturing process provides the most
information capacity available today on an array, enabling
researchers to use a whole-genome approach to analyzing the
relationship between genetics and health. Affymetrix is
headquartered in Santa Clara, Calif., with manufacturing facilities
in Sacramento, Calif., and Bedford, Mass. The company maintains
important sales and marketing operations in Europe and Asia and has
about 1,100 employees worldwide. For more information about
Affymetrix, please visit the company's website at
www.affymetrix.com. All statements in this press release that are
not historical are "forward-looking statements" within the meaning
of Section 21E of the Securities Exchange Act as amended, including
statements regarding Affymetrix' "expectations," "beliefs,"
"hopes," "intentions," "strategies," or the like. Such statements
are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected,
including, but not limited to: risks and uncertainties associated
with the agreement between Affymetrix and Wyeth discussed in this
press release; risks of the Company's ability to achieve and
sustain higher levels of revenue, higher gross margins, reduced
operating expenses; uncertainties relating to technological
approaches, manufacturing, product development; personnel
retention; uncertainties related to cost and pricing of Affymetrix
products; dependence on collaborative partners; uncertainties
relating to sole source suppliers; uncertainties relating to FDA
and other regulatory approvals; competition; risks relating to
intellectual property of others and the uncertainties of patent
protection and litigation. These and other risk factors are
discussed in Affymetrix' Form 10-K/A for the year ended December
31, 2005, and other SEC reports, including its Quarterly Reports on
Form 10-Q for subsequent quarterly periods. Affymetrix expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in Affymetrix' expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based. NOTE: Affymetrix, the
Affymetrix logo, and GeneChip are registered trademarks owned or
used by Affymetrix Inc. Affymetrix Inc. (Nasdaq: AFFX) announced
today that Wyeth (NYSE: WYE) has signed another agreement with
Affymetrix to use GeneChip(R) microarray technology for three more
years, further extending the relationship that began in 1994. Under
the agreement, Wyeth will continue to apply Affymetrix technology
in numerous areas of the drug discovery and development process.
Wyeth was one of the first pharmaceutical companies to apply
genomics in clinical research. The company will continue to use
Affymetrix microarray technology to identify new drug targets and
gain a better understanding of the genetic markers that potentially
correlate with a patient's response to therapy. The latest GeneChip
technology enables them to more accurately classify disease,
predict clinical progression and determine likelihoods of treatment
success in ways never before possible. "Wyeth has been a pioneer in
demonstrating the power of Affymetrix microarray technology in the
entire drug discovery and development process," said Chip Leveille,
vice president, Pharmaceutical Business Unit at Affymetrix. "We
anticipate that a better understanding of human genetic variations
and the ability to look at the entire genome in greater detail will
dramatically accelerate research and, ultimately, help bring more
effective tests and therapies to market faster." About Affymetrix
Affymetrix scientists invented the world's first high-density
microarray in 1989 and began selling the first commercial
microarray in 1994. Since then, Affymetrix GeneChip(R) technology
has become the industry standard in molecular biology research.
Affymetrix technology is used by the world's top pharmaceutical,
diagnostic and biotechnology companies as well as leading academic,
government and not-for-profit research institutes. More than 1,400
systems have been installed around the world and more than 7,000
peer-reviewed papers have been published using the technology.
Affymetrix' patented photolithographic manufacturing process
provides the most information capacity available today on an array,
enabling researchers to use a whole-genome approach to analyzing
the relationship between genetics and health. Affymetrix is
headquartered in Santa Clara, Calif., with manufacturing facilities
in Sacramento, Calif., and Bedford, Mass. The company maintains
important sales and marketing operations in Europe and Asia and has
about 1,100 employees worldwide. For more information about
Affymetrix, please visit the company's website at
www.affymetrix.com. All statements in this press release that are
not historical are "forward-looking statements" within the meaning
of Section 21E of the Securities Exchange Act as amended, including
statements regarding Affymetrix' "expectations," "beliefs,"
"hopes," "intentions," "strategies," or the like. Such statements
are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected,
including, but not limited to: risks and uncertainties associated
with the agreement between Affymetrix and Wyeth discussed in this
press release; risks of the Company's ability to achieve and
sustain higher levels of revenue, higher gross margins, reduced
operating expenses; uncertainties relating to technological
approaches, manufacturing, product development; personnel
retention; uncertainties related to cost and pricing of Affymetrix
products; dependence on collaborative partners; uncertainties
relating to sole source suppliers; uncertainties relating to FDA
and other regulatory approvals; competition; risks relating to
intellectual property of others and the uncertainties of patent
protection and litigation. These and other risk factors are
discussed in Affymetrix' Form 10-K/A for the year ended December
31, 2005, and other SEC reports, including its Quarterly Reports on
Form 10-Q for subsequent quarterly periods. Affymetrix expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in Affymetrix' expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based. NOTE: Affymetrix, the
Affymetrix logo, and GeneChip are registered trademarks owned or
used by Affymetrix Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024